Safety And Clinical Outcomes Of Radium-223 With Concomitant Radiotherapy Or Subsequent Treatment With The Investigational Agent 177Lu-PSMA In Patients With Metastatic Castration-Resistant Prostate Cancer: An Interim Analysis Of The REASSURE Study.

Authors :: Song, D.
Zimberg, S.H.
Conti, P.
la Fougère, C.
Essler, M.
Kramer, G.
Ellinger, J.
Sylvester, J.E.
Paganelli, G.
Peer, A.
Bögemann, M.
George, S.
Tomaszewski, J.
Meltzer, J.
Sandström, P.
Babajanyan, S.
Nordquist, L.
Sartor, O.
Source :: International Journal of Radiation Oncology, Biology, Physics. 2020 Supplement, Vol. 108 Issue 3, pe854-e855. 2p.
Publication Year :: 2020

Subjects :: *INVESTIGATIONAL therapies
*CASTRATION-resistant prostate cancer
*PROSTATE cancer
*RADIOTHERAPY

Full Text Access

Tools